Subtype
Bladder Neoplasm
CI-CAN-00001978Explore in graph →
Non-malignant390 active trials10 approved drugs25 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001978Explore in graph →
Clinical trials
1,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00088946 | Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer | completed | Phase 2 | 17 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT03167151 | Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)(PemBla) | terminated | Phase 1 / Phase 2 | 6 | University of OxfordOTHER | 1 | Jul 31, 2020 |
| clinicaltrials |
| NCT04493489 | Propranolol Adjuvant Treatment of Bladder Cancer | unknown | Phase 2 | 242 | Central South UniversityOTHER | 0 | Jul 30, 2020 | clinicaltrials |
| NCT04219046 | Evaluation of Naloxegol in the Prevention of POI After Cystectomy(ANTAGOCYST) | unknown | Phase 2 | 102 | Institut Paoli-CalmettesOTHER | 0 | Jul 28, 2020 | clinicaltrials |
| NCT03672240 | Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment(NMIBC) | completed | Phase 1 / Phase 2 | 6 | Asieris Pharmaceutical Technologies Co., Ltd.INDUSTRY | 1 | Jul 20, 2020 | clinicaltrials |
| NCT02169284 | Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jul 7, 2020 | clinicaltrials |
| NCT02447549 | Study of Tumour Focused Radiotherapy for Bladder Cancer(RAIDER) | active not recruiting | Phase 2 | 345 | Institute of Cancer Research, United KingdomOTHER | 3 | Jun 9, 2020 | clinicaltrials |
| NCT03517995 | Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention | withdrawn | Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT00462488 | Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ | completed | Phase 2 | 46 | Sesen Bio, Inc.INDUSTRY | 2 | May 12, 2020 | clinicaltrials |
| NCT03534492 | Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)(NEODURVARIB) | completed | Phase 2 | 29 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT02070120 | Investigating Bladder Chemotherapy Instead of Surgery for Low Risk Bladder Cancer(CALIBER) | unknown | Phase 2 | 82 | Institute of Cancer Research, United KingdomOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT02028442 | Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients(EVOLVE) | completed | Phase 1 / Phase 2 | 61 | Akamis BioINDUSTRY | 2 | Mar 12, 2020 | clinicaltrials |
| NCT02010203 | A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT | terminated | Phase 1 / Phase 2 | 104 | Heat BiologicsINDUSTRY | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01094496 | A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study) | terminated | Phase 2 | 3 | Celldex TherapeuticsINDUSTRY | 1 | Feb 13, 2020 | clinicaltrials |
| NCT03935347 | Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT00978250 | A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) | completed | Phase 2 | 95 | National Cancer Institute (NCI)NIH | 1 | Dec 27, 2019 | clinicaltrials |
| NCT00722553 | Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder | completed | Phase 2 | 30 | Acrotech Biopharma Inc.INDUSTRY | 6 | Dec 17, 2019 | clinicaltrials |
| NCT04040725 | Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Dec 17, 2019 | clinicaltrials |
| NCT02178241 | Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 2 | Dec 16, 2019 | clinicaltrials |
| NCT02665039 | A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function(VINGEM) | completed | Phase 2 | 62 | Dr Anders UllénOTHER | 2 | Oct 8, 2019 | clinicaltrials |
| NCT01589094 | Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 2, 2019 | clinicaltrials |
| NCT00794950 | Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma(Sutent) | completed | Phase 2 | 43 | University of MichiganOTHER | 1 | Sep 23, 2019 | clinicaltrials |
| NCT02141490 | Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers | completed | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 6, 2019 | clinicaltrials |
| NCT02999672 | A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors(KAMELEON) | completed | Phase 2 | 20 | Hoffmann-La RocheINDUSTRY | 4 | Aug 28, 2019 | clinicaltrials |
| NCT04060459 | Paclitaxel-binding Albumin and Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer | unknown | Phase 2 | 50 | Third Military Medical UniversityOTHER | 1 | Aug 19, 2019 | clinicaltrials |
| NCT01373294 | Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer | completed | Phase 2 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 6, 2019 | clinicaltrials |
| NCT01611662 | Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer | terminated | Phase 2 | 32 | Fox Chase Cancer CenterOTHER | 1 | Jul 29, 2019 | clinicaltrials |
| NCT02153905 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2019 | clinicaltrials |
| NCT03982797 | Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis | unknown | Phase 2 | 306 | Biofabri, S.LINDUSTRY | 1 | Jun 12, 2019 | clinicaltrials |
| NCT02355886 | Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy | completed | Phase 2 / Phase 3 | 25 | University of WashingtonOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT01191892 | Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer | completed | Phase 2 | 82 | Cardiff UniversityOTHER | 1 | May 16, 2019 | clinicaltrials |
| NCT01118351 | Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer | terminated | Phase 2 | 19 | Case Comprehensive Cancer CenterOTHER | 1 | May 1, 2019 | clinicaltrials |
| NCT00595088 | Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer | completed | Phase 2 | 47 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 2 | Apr 30, 2019 | clinicaltrials |
| NCT01342172 | Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma | terminated | Phase 1 / Phase 2 | 9 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Apr 23, 2019 | clinicaltrials |
| NCT00526656 | Sunitinib in Treating Patients With Locally Advanced Bladder Cancer | completed | Phase 2 | 9 | Case Comprehensive Cancer CenterOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02109328 | Alisertib in Chemotherapy-pretreated Urothelial Cancer | completed | Phase 2 | 22 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Apr 11, 2019 | clinicaltrials |
| NCT01435356 | Safety and Efficacy Study of MAGE-A3 + AS-15 in Patients With Muscle-invasive Bladder Cancer After Cystectomy(MAGNOLIA) | terminated | Phase 2 | 83 | European Association of Urology Research FoundationOTHER | 10 | Jan 9, 2019 | clinicaltrials |
| NCT03419130 | Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer | withdrawn | Phase 2 | 0 | University of California, San FranciscoOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT02560038 | Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer | terminated | Phase 2 | 3 | The University of Texas Health Science Center, HoustonOTHER | 1 | Nov 28, 2018 | clinicaltrials |
| NCT02605863 | Enzalutamide for Bladder Cancer Chemoprevention | terminated | Phase 2 | 1 | University of RochesterOTHER | 1 | Oct 3, 2018 | clinicaltrials |
| NCT00880334 | Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC | completed | Phase 2 | 149 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT00578526 | SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial(SPRUCE) | completed | Phase 2 | 64 | AHS Cancer Control AlbertaOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT00310011 | Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium | completed | Phase 2 | 71 | Wake Forest University Health SciencesOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT00112671 | Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2018 | clinicaltrials |
| NCT00089128 | Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer | terminated | Phase 2 | 16 | Medical University of South CarolinaOTHER | 1 | Jul 12, 2018 | clinicaltrials |
| NCT00268450 | Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery | terminated | Phase 2 | 21 | Medical University of South CarolinaOTHER | 1 | Jul 12, 2018 | clinicaltrials |
| NCT00055601 | Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer | completed | Phase 2 | 97 | Radiation Therapy Oncology GroupNETWORK | 1 | Jun 15, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Jul 31, 2020source: clinicaltrials